aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given an average recommendation of “Hold” by the eight brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company.

Several equities analysts recently commented on the stock. Weiss Ratings raised shares of aTyr Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th.

Insider Activity at aTyr Pharma

In related news, Director Paul Schimmel acquired 100,000 shares of the stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average cost of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. This represents a 14.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.75% of the company’s stock.

Hedge Funds Weigh In On aTyr Pharma

Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System acquired a new stake in aTyr Pharma during the 2nd quarter worth about $28,000. Renaissance Technologies LLC purchased a new stake in aTyr Pharma during the 1st quarter valued at about $32,000. ADAR1 Capital Management LLC grew its stake in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after purchasing an additional 13,385 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of aTyr Pharma in the fourth quarter valued at about $41,000. Finally, Legal & General Group Plc acquired a new position in shares of aTyr Pharma in the second quarter valued at about $49,000. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Price Performance

Shares of ATYR stock opened at $0.53 on Friday. aTyr Pharma has a 1-year low of $0.40 and a 1-year high of $6.50. The stock’s fifty day moving average price is $0.52 and its 200 day moving average price is $0.68. The company has a market cap of $51.99 million, a price-to-earnings ratio of -0.85 and a beta of 0.54.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $189.56 million during the quarter. As a group, equities research analysts anticipate that aTyr Pharma will post -0.44 earnings per share for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.